메뉴 건너뛰기




Volumn 61, Issue 6, 2012, Pages 918-932

New therapies for inflammatory bowel disease: From the bench to the bedside

(1)  Danese, Silvio a  

a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFLAMMATORY AGENT; APILIMOD; AZATHIOPRINE; BASILIXIMAB; BETA INTERFERON; BRIAKINUMAB; CERTOLIZUMAB PEGOL; DACLIZUMAB; DEBIO 01512; DERSALAZINE; FONTOLIZUMAB; GOLIMUMAB; HMPL 004; INFLIXIMAB; OZORALIZUMAB; PLACEBO; PREDNISOLONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RITUXIMAB; SCH 900222; SIRUKUMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VISILIZUMAB;

EID: 84860557456     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300904     Document Type: Review
Times cited : (256)

References (144)
  • 1
    • 34248136828 scopus 로고    scopus 로고
    • Inflammatory bowel disease: cause and immunobiology
    • DOI 10.1016/S0140-6736(07)60750-8, PII S0140673607607508
    • Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40. (Pubitemid 46722636)
    • (2007) Lancet , vol.369 , Issue.9573 , pp. 1627-1640
    • Baumgart, D.C.1    Carding, S.R.2
  • 2
    • 77955708883 scopus 로고    scopus 로고
    • New pathophysiological insights and modern treatment of IBD
    • Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-83.
    • (2010) J Gastroenterol , vol.45 , pp. 571-583
    • Engel, M.A.1    Neurath, M.F.2
  • 3
    • 79953786419 scopus 로고    scopus 로고
    • Loss of response and need for adalimumab dose intensification in Crohn's disease: A systematic review
    • Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011;106:674-84.
    • (2011) Am J Gastroenterol , vol.106 , pp. 674-684
    • Billioud, V.1    Sandborn, W.J.2    Peyrin-Biroulet, L.3
  • 4
    • 62049083383 scopus 로고    scopus 로고
    • Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review
    • Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
    • (2009) Am J Gastroenterol , vol.104 , pp. 760-767
    • Gisbert, J.P.1    Panes, J.2
  • 5
    • 79952788410 scopus 로고    scopus 로고
    • Review article: Remission rates achievable by current therapies for inflammatory bowel disease
    • Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:870-9.
    • (2011) Aliment Pharmacol Ther , vol.33 , pp. 870-879
    • Peyrin-Biroulet, L.1    Lemann, M.2
  • 7
    • 69449105914 scopus 로고    scopus 로고
    • Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease
    • Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009;206:1883-97.
    • (2009) J Exp Med , vol.206 , pp. 1883-1897
    • Smith, A.M.1    Rahman, F.Z.2    Hayee, B.3
  • 8
    • 46149125761 scopus 로고    scopus 로고
    • Crohn's disease: beyond antagonists of tumour necrosis factor
    • DOI 10.1016/S0140-6736(08)60995-2, PII S0140673608609952
    • Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, et al. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81. (Pubitemid 351902263)
    • (2008) The Lancet , vol.372 , Issue.9632 , pp. 67-81
    • Peyrin-Biroulet, L.1    Desreumaux, P.2    Sandborn, W.J.3    Colombel, J.-F.4
  • 10
    • 33847206969 scopus 로고    scopus 로고
    • IL-17 family cytokines and the expanding diversity of effector T cell lineages
    • DOI 10.1146/annurev.immunol.25.022106.141557
    • Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52. (Pubitemid 46697925)
    • (2007) Annual Review of Immunology , vol.25 , pp. 821-852
    • Weaver, C.T.1    Hatton, R.D.2    Mangan, P.R.3    Harrington, L.E.4
  • 11
    • 33646804892 scopus 로고    scopus 로고
    • Critical role of IL-17 receptor signalling in acute TNBS-induced colitis
    • Zhang Z, Zheng M, Bindas J, et al. Critical role of IL-17 receptor signalling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12:382-8.
    • (2006) Inflamm Bowel Dis , vol.12 , pp. 382-388
    • Zhang, Z.1    Zheng, M.2    Bindas, J.3
  • 12
    • 79955551587 scopus 로고    scopus 로고
    • Regulation of homeostasis and inflammation in the intestine
    • MacDonald TT, Monteleone I, Fantini MC, et al. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011;140:1768-75.
    • (2011) Gastroenterology , vol.140 , pp. 1768-1775
    • MacDonald, T.T.1    Monteleone, I.2    Fantini, M.C.3
  • 14
    • 0036107919 scopus 로고    scopus 로고
    • Immunoregulation in the gut: Success and failures in human disease
    • Monteleone I, Vavassori P, Biancone L, et al. Immunoregulation in the gut: success and failures in human disease. Gut 2002;50: iii60-4. (Pubitemid 34407458)
    • (2002) Gut , vol.50 , Issue.SUPPL. 3
    • Monteleone, I.1    Vavassori, P.2    Biancone, L.3    Monteleone, G.4    Pallone, F.5
  • 15
    • 80955178844 scopus 로고    scopus 로고
    • Surgery for adult Crohn's disease: What is the actual risk?
    • Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011;60:1178-81.
    • (2011) Gut , vol.60 , pp. 1178-1181
    • Bouguen, G.1    Peyrin-Biroulet, L.2
  • 16
    • 79952582391 scopus 로고    scopus 로고
    • Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis
    • Semerano L, Assier E, Delavallee L, et al. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther 2011;11:545-50.
    • (2011) Expert Opin Biol Ther , vol.11 , pp. 545-550
    • Semerano, L.1    Assier, E.2    Delavallee, L.3
  • 17
    • 77952514447 scopus 로고    scopus 로고
    • Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: A long-term study in a transgenic model of arthritis
    • Delavallee L, Semerano L, Assier E, et al. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009;11:R195.
    • (2009) Arthritis Res Ther , vol.11
    • Delavallee, L.1    Semerano, L.2    Assier, E.3
  • 20
    • 84860583009 scopus 로고    scopus 로고
    • Active therapeutic immunization against TNF with a TNF-kinoid in Crohn's disease patients: A phase 1-2 study
    • Rogler G, Michetti PF, Kruger FC, et al. Active therapeutic immunization against TNF with a TNF-kinoid in Crohn's disease patients: a phase 1-2 study. Digestive Disease Week 2010;140: T1234.
    • (2010) Digestive Disease Week , vol.140
    • Rogler, G.1    Michetti, P.F.2    Kruger, F.C.3
  • 22
    • 77953693548 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease
    • Sands BE, Jacobson EW, Sylwestrowicz T, et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 2010;16:1209-18.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 1209-1218
    • Sands, B.E.1    Jacobson, E.W.2    Sylwestrowicz, T.3
  • 23
    • 53049091561 scopus 로고    scopus 로고
    • A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
    • Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;35:1130-41.
    • (2008) Gastroenterology , vol.35 , pp. 1130-1141
    • Sandborn, W.J.1    Feagan, B.G.2    Fedorak, R.N.3
  • 24
    • 72049124819 scopus 로고    scopus 로고
    • Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease
    • Toedter GP, Blank M, Lang Y, et al. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol 2009;104:2768-73.
    • (2009) Am J Gastroenterol , vol.104 , pp. 2768-2773
    • Toedter, G.P.1    Blank, M.2    Lang, Y.3
  • 25
    • 81255206921 scopus 로고    scopus 로고
    • A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severly active Crohn's disease: Results through week 22 from the Certifi trial
    • Sandborn WJ, Gasink C, Gao LL, et al. A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severly active Crohn's disease: results through week 22 from the Certifi trial. Digestive Disease Week 2011;140:A592.
    • (2011) Digestive Disease Week , vol.140
    • Sandborn, W.J.1    Gasink, C.2    Gao, L.L.3
  • 28
    • 84860599482 scopus 로고    scopus 로고
    • US National Institutes of Health. ClinicalTrials.gov [Online] accessed Jul 2011
    • US National Institutes of Health. ClinicalTrials.gov [Online]. 2011. http://www.clinicaltrials.gov (accessed Jul 2011).
    • (2011)
  • 29
    • 10744232542 scopus 로고    scopus 로고
    • Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis
    • Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18:65-75.
    • (2003) Aliment Pharmacol Ther , vol.18 , pp. 65-75
    • Creed, T.J.1    Norman, M.R.2    Probert, C.S.3
  • 30
    • 33646232018 scopus 로고    scopus 로고
    • Basiliximab for the treatment of steroid-resistant ulcerative colitis: Further experience in moderate and severe disease
    • Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006;23:1435-42.
    • (2006) Aliment Pharmacol Ther , vol.23 , pp. 1435-1442
    • Creed, T.J.1    Probert, C.S.2    Norman, M.N.3
  • 35
    • 73949092345 scopus 로고    scopus 로고
    • Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
    • Reinisch W, de Villiers WJ, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16:233-42.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 233-242
    • Reinisch, W.1    De Villiers, W.J.2    Bene, L.3
  • 36
    • 34548190038 scopus 로고    scopus 로고
    • IL-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance
    • DOI 10.1002/ibd.20148
    • Mudter J, Neurath MF. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007;13:1016-23. (Pubitemid 47309974)
    • (2007) Inflammatory Bowel Diseases , vol.13 , Issue.8 , pp. 1016-1023
    • Mudter, J.1    Neurath, M.F.2
  • 37
    • 76149132672 scopus 로고    scopus 로고
    • Early-onset Crohn disease is associated with male sex and a polymorphism in the IL-6 promoter
    • Sagiv-Friedgut K, Karban A, Weiss B, et al. Early-onset Crohn disease is associated with male sex and a polymorphism in the IL-6 promoter. J Pediatr Gastroenterol Nutr 2010;50:22-6.
    • (2010) J Pediatr Gastroenterol Nutr , vol.50 , pp. 22-26
    • Sagiv-Friedgut, K.1    Karban, A.2    Weiss, B.3
  • 38
    • 77951188458 scopus 로고    scopus 로고
    • Upregulation of DNA methyltransferase-mediated gene silencing, anchorageindependent growth, and migration of colon cancer cells by interleukin-6
    • Foran E, Garrity-Park MM, Mureau C, et al. Upregulation of DNA methyltransferase-mediated gene silencing, anchorageindependent growth, and migration of colon cancer cells by interleukin-6. Mol Cancer Res 2010;8:471-81.
    • (2010) Mol Cancer Res , vol.8 , pp. 471-481
    • Foran, E.1    Garrity-Park, M.M.2    Mureau, C.3
  • 39
    • 77149155643 scopus 로고    scopus 로고
    • Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis
    • Li Y, de Haar C, Chen M, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010;59:227-35.
    • (2010) Gut , vol.59 , pp. 227-235
    • Li, Y.1    De Haar, C.2    Chen, M.3
  • 40
    • 77949326158 scopus 로고    scopus 로고
    • Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages,on the development of colitis-associated premalignant cancer in a murine model
    • Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages,on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010;184:1543-51.
    • (2010) J Immunol , vol.184 , pp. 1543-1551
    • Matsumoto, S.1    Hara, T.2    Mitsuyama, K.3
  • 41
    • 79960182099 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics, and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study
    • Xu Y, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics, and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72:270-81.
    • (2011) Br J Clin Pharmacol , vol.72 , pp. 270-281
    • Xu, Y.1    Bouman-Thio, E.2    Comisar, C.3
  • 42
    • 77956646068 scopus 로고    scopus 로고
    • Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: Meta-analysis of six initial trials and five long-term extensions
    • Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-32.
    • (2010) Mod Rheumatol , vol.20 , pp. 222-232
    • Nishimoto, N.1    Ito, K.2    Takagi, N.3
  • 43
    • 73449118587 scopus 로고    scopus 로고
    • Comparison of tociliziumab monotherapy versus methotrexate monotherapy in patients with moderate to sever rheumatoid arthritis: The AMBITION study
    • Jones G, Sebba A, Gu J, et al. Comparison of tociliziumab monotherapy versus methotrexate monotherapy in patients with moderate to sever rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
    • (2010) Ann Rheum Dis , vol.69 , pp. 88-96
    • Jones, G.1    Sebba, A.2    Gu, J.3
  • 44
    • 77958521437 scopus 로고    scopus 로고
    • accessed Jul 2011
    • US Food and Drug Administration. FDA Approves New Drug for Rheumatoid Arthritis. 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm197108.htm (accessed Jul 2011).
    • (2010) FDA Approves New Drug for Rheumatoid Arthritis
  • 47
    • 79952445609 scopus 로고    scopus 로고
    • IBD: Of mice and men - Shedding new light on IL-13 activity in IBD
    • Danese S. IBD: of mice and men - shedding new light on IL-13 activity in IBD. Nat Rev Gastroenterol Hepatol 2011;8:128-9.
    • (2011) Nat Rev Gastroenterol Hepatol , vol.8 , pp. 128-129
    • Danese, S.1
  • 48
    • 79952532799 scopus 로고    scopus 로고
    • Suppression of inflammation in ulcerative colitis by interferon-b-1a is accompanied by inhibition of IL-13 production
    • Mannon PJ, Hornung RL, Yang Z, et al. Suppression of inflammation in ulcerative colitis by interferon-b-1a is accompanied by inhibition of IL-13 production. Gut 2011;60:449-55.
    • (2011) Gut , vol.60 , pp. 449-455
    • Mannon, P.J.1    Hornung, R.L.2    Yang, Z.3
  • 49
    • 78649829431 scopus 로고    scopus 로고
    • Colitis and intestinal inflammation in IL10-/- mice results from IL-13Ra2-mediated attenuation of IL-13 activity
    • Wilson MS, Ramalingam TR, Rivollier A, et al. Colitis and intestinal inflammation in IL10-/- mice results from IL-13Ra2-mediated attenuation of IL-13 activity. Gastroenterology 2011;140:254-64.
    • (2011) Gastroenterology , vol.140 , pp. 254-264
    • Wilson, M.S.1    Ramalingam, T.R.2    Rivollier, A.3
  • 50
    • 66149159613 scopus 로고    scopus 로고
    • IL-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease
    • Liu Z, Yang L, Cui Y, et al. IL-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:1133-44.
    • (2009) Inflamm Bowel Dis , vol.15 , pp. 1133-1144
    • Liu, Z.1    Yang, L.2    Cui, Y.3
  • 52
    • 79952435375 scopus 로고    scopus 로고
    • Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis
    • Ajdukovic J, Tonkic A, Salamunic I, et al. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Hepatogastroenterology 2010;57:1442-4.
    • (2010) Hepatogastroenterology , vol.57 , pp. 1442-1444
    • Ajdukovic, J.1    Tonkic, A.2    Salamunic, I.3
  • 53
    • 72549107316 scopus 로고    scopus 로고
    • Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease
    • Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009;58:1629-36.
    • (2009) Gut , vol.58 , pp. 1629-1636
    • Rovedatti, L.1    Kudo, T.2    Biancheri, P.3
  • 55
    • 34547557700 scopus 로고    scopus 로고
    • Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation
    • Naftali T, Novick D, Gabay G, et al. Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation. Isr Med Assoc J 2007;9:504-8. (Pubitemid 47193376)
    • (2007) Israel Medical Association Journal , vol.9 , Issue.7 , pp. 504-508
    • Naftali, T.1    Novick, D.2    Gabay, G.3    Rubinstein, M.4    Novis, B.5
  • 57
    • 80052100689 scopus 로고    scopus 로고
    • T cell responses: Anger management for TH17 cells
    • Bordon Y. T cell responses: anger management for TH17 cells. Nat Rev Immunol 2011;11:567-632.
    • (2011) Nat Rev Immunol , vol.11 , pp. 567-632
    • Bordon, Y.1
  • 58
    • 84860582481 scopus 로고    scopus 로고
    • Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study
    • Stockholm, September 25-26th 2011, European Cancer Organisation
    • Herrlinger KR, Diculescu M, Fellermann K, et al. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. 6th Congress of ECCO 2011:P209. Stockholm, September 25-26th 2011, European Cancer Organisation.
    • 6th Congress of ECCO 2011 , pp. 209
    • Herrlinger, K.R.1    Diculescu, M.2    Fellermann, K.3
  • 60
    • 78650362917 scopus 로고    scopus 로고
    • Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection
    • Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-84.
    • (2010) J Med Chem , vol.53 , pp. 8468-8484
    • Flanagan, M.E.1    Blumenkopf, T.A.2    Brissette, W.H.3
  • 61
    • 79955027327 scopus 로고    scopus 로고
    • Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)
    • Ghoreschi K, Jesson MI, Lee JL, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234-43.
    • (2011) J Immunol , vol.186 , pp. 4234-4243
    • Ghoreschi, K.1    Jesson, M.I.2    Lee, J.L.3
  • 62
    • 84859050689 scopus 로고    scopus 로고
    • Phase 2 randomized study of CP-690,550, an oral janus kinase inhibitor, in active Crohn's disease
    • Sandborn WJ, Ghosh S, Panes J, et al. Phase 2 randomized study of CP-690,550, an oral janus kinase inhibitor, in active Crohn's disease. Digestive Disease Week 2011;140:A745.
    • (2011) Digestive Disease Week , vol.140
    • Sandborn, W.J.1    Ghosh, S.2    Panes, J.3
  • 63
    • 84859050689 scopus 로고    scopus 로고
    • Phase 2 study of CP- 690,550, and oral janus kinase inhibitor, in active ulcerative colitis
    • Sandborn WJ, Ghosh S, Panes J, et al. Phase 2 study of CP- 690,550, and oral janus kinase inhibitor, in active ulcerative colitis. Digestive Disease Week 2011;140:A594.
    • (2011) Digestive Disease Week , vol.140
    • Sandborn, W.J.1    Ghosh, S.2    Panes, J.3
  • 65
    • 0031903013 scopus 로고    scopus 로고
    • Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation
    • Nikolaus S, Bauditz J, Gionchetti P, et al. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998;42:470-6. (Pubitemid 28186561)
    • (1998) Gut , vol.42 , Issue.4 , pp. 470-476
    • Nikolaus, S.1    Bauditz, J.2    Gionchetti, P.3    Witt, C.4    Lochs, H.5    Schreiber, S.6
  • 66
    • 55049111426 scopus 로고    scopus 로고
    • Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility
    • Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008;40:1319-23.
    • (2008) Nat Genet , vol.40 , pp. 1319-1323
    • Franke, A.1    Balschun, T.2    Karlsen, T.H.3
  • 67
    • 0030835754 scopus 로고    scopus 로고
    • Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
    • DOI 10.1053/gast.1997.v113.pm9247454
    • van Deventer SJ, Elson CO, Fedorak R. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997;113:383-9. (Pubitemid 27351761)
    • (1997) Gastroenterology , vol.113 , Issue.2 , pp. 383-389
    • Van Deventer, S.J.H.1    Elson, C.O.2    Fedorak, R.N.3
  • 74
    • 33645455612 scopus 로고    scopus 로고
    • Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease
    • Herrlinger KR, Witthoeft T, Raedler A, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006;101:793-7.
    • (2006) Am J Gastroenterol , vol.101 , pp. 793-797
    • Herrlinger, K.R.1    Witthoeft, T.2    Raedler, A.3
  • 75
    • 0036024194 scopus 로고    scopus 로고
    • Induction and maintenance of clinical remission by interferon-beta in patients wih steroidrefractory active ulcerative colitis-an open long-term pilot trial
    • Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients wih steroidrefractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther 2002;17:1233-9.
    • (2002) Aliment Pharmacol Ther , vol.17 , pp. 1233-1239
    • Musch, E.1    Andus, T.2    Malek, M.3
  • 77
    • 38349057988 scopus 로고    scopus 로고
    • Successful treatment of steroid refractory active ulcerative colitis with natural interferonbeta e an open long-term trial
    • Musch E, Andus T, Malek M, et al. Successful treatment of steroid refractory active ulcerative colitis with natural interferonbeta e an open long-term trial. Z Gastroenterol 2007;45:1235-40.
    • (2007) Z Gastroenterol , vol.45 , pp. 1235-1240
    • Musch, E.1    Andus, T.2    Malek, M.3
  • 79
    • 49849103846 scopus 로고    scopus 로고
    • Clinical trial: A multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis
    • Pena Rossi C, Schrieber S, Golubovic G, et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:758-67.
    • (2008) Aliment Pharmacol Ther , vol.28 , pp. 758-767
    • Pena Rossi, C.1    Schrieber, S.2    Golubovic, G.3
  • 80
    • 65149091969 scopus 로고    scopus 로고
    • Interferon beta- 1a for the maintenance of remission in patients with Crohn's disease: Results of a phase II dose-finding study
    • Pena Rossi C, Hanauer SB, Tomasevic R, et al. Interferon beta- 1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. Gastroenterology 2009;29:22.
    • (2009) Gastroenterology , vol.29 , pp. 22
    • Pena Rossi, C.1    Hanauer, S.B.2    Tomasevic, R.3
  • 82
    • 79951990263 scopus 로고    scopus 로고
    • Localized delivery of interferon-10 by Lactobacillus exacerbates experimental colitis
    • McFarland AP, Savan R, Wagage S, et al. Localized delivery of interferon-10 by Lactobacillus exacerbates experimental colitis. PLoS One 2011;6:e16967.
    • (2011) PLoS One , vol.6
    • McFarland, A.P.1    Savan, R.2    Wagage, S.3
  • 83
    • 34047186008 scopus 로고    scopus 로고
    • T cell costimulation: A rational target in the therapeutic armamentarium for autoimmune diseases and transplantation
    • DOI 10.1146/annurev.med.58.080205.154004
    • Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune disease and transplantation. Annu Rev Med 2007;58:347-58. (Pubitemid 46706519)
    • (2007) Annual Review of Medicine , vol.58 , pp. 347-358
    • Vincenti, F.1    Luggen, M.2
  • 84
    • 4344594765 scopus 로고    scopus 로고
    • A humanised anti-CD3 monoclonal antibody, visiluzumab, for treatment of severe steroid refractory ulcerative colitis: Preliminary results of a phase 1 study
    • abstract
    • Plevy SE, Salzberg BA, Requerio M. A humanised anti-CD3 monoclonal antibody, visiluzumab, for treatment of severe steroid refractory ulcerative colitis: preliminary results of a phase 1 study (abstract). Gastroenterology 2003;126:A75.
    • (2003) Gastroenterology , vol.126
    • Plevy, S.E.1    Salzberg, B.A.2    Requerio, M.3
  • 86
    • 77949507036 scopus 로고    scopus 로고
    • Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis
    • Baumgart DC, Targan SR, Dignass AU, et al. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2010;16:620-9.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 620-629
    • Baumgart, D.C.1    Targan, S.R.2    Dignass, A.U.3
  • 87
    • 78049514932 scopus 로고    scopus 로고
    • Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis
    • Sandborn WJ, Colombel J-F, Frankel M, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid- refractory ulcerative colitis. Gut 2010;59:1485-92.
    • (2010) Gut , vol.59 , pp. 1485-1492
    • Sandborn, W.J.1    Colombel, J.-F.2    Frankel, M.3
  • 88
    • 65449120762 scopus 로고    scopus 로고
    • Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease
    • Baumgart DC, Lowder JN, Targan SR, et al. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol 2009;104:868-76.
    • (2009) Am J Gastroenterol , vol.104 , pp. 868-876
    • Baumgart, D.C.1    Lowder, J.N.2    Targan, S.R.3
  • 89
    • 80053566144 scopus 로고    scopus 로고
    • Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis
    • Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011;60:1520-6.
    • (2011) Gut , vol.60 , pp. 1520-1526
    • Leiper, K.1    Martin, K.2    Ellis, A.3
  • 90
    • 79952078492 scopus 로고    scopus 로고
    • Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma
    • Blombery P, Prince HM, Levinson M, et al. Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol 2011;29:e110-12.
    • (2011) J Clin Oncol , vol.29
    • Blombery, P.1    Prince, H.M.2    Levinson, M.3
  • 91
    • 42549142171 scopus 로고    scopus 로고
    • Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease
    • DOI 10.1136/gut.2007.138305
    • El Fassi D, Nielsen CH, Kjeldsen J, et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Grave's disease. Gut 2008;57:714-15. (Pubitemid 351579988)
    • (2008) Gut , vol.57 , Issue.5 , pp. 714-715
    • El, F.D.1    Nielsen, C.H.2    Kjeldsen, J.3    Clemmensen, O.4    Hegedus, L.5
  • 92
    • 77954362764 scopus 로고    scopus 로고
    • Severe ulcerative colitis after rituximab therapy
    • Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 2010;126:e243-6.
    • (2010) Pediatrics , vol.126
    • Ardelean, D.S.1    Gonska, T.2    Wires, S.3
  • 94
    • 79955572862 scopus 로고    scopus 로고
    • DDW 2010 649: A randomized placebo-controlled trial of abatacept for moderately-to-severely active Crohn's disease (CD)
    • Hanauer SB, Sandborn WJ, Sands BE, et al. DDW 2010 649: a randomized placebo-controlled trial of abatacept for moderately-to-severely active Crohn's disease (CD). Gastroenterology 2010;138(Suppl 1):S-86.
    • (2010) Gastroenterology , vol.138 , Issue.SUPPL. 1
    • Hanauer, S.B.1    Sandborn, W.J.2    Sands, B.E.3
  • 95
    • 84860599481 scopus 로고    scopus 로고
    • A study of abatacept in patients with active ulcerative colitis
    • Abstract. accessed Jul 2011
    • Sandborn WJ, et al. A study of abatacept in patients with active ulcerative colitis. American College of Gastroenterology Annual Meeting; 2009;Abstract. http://clinicaltrial.gov (accessed Jul 2011)
    • American College of Gastroenterology Annual Meeting; 2009
    • Sandborn, W.J.1
  • 99
    • 0347987896 scopus 로고    scopus 로고
    • An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease
    • DOI 10.1159/000074517
    • Dejaco C, Lichtenberger C, Miehsler W, et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion 2003;68:63-70. (Pubitemid 38056704)
    • (2003) Digestion , vol.68 , Issue.2-3 , pp. 63-70
    • Dejaco, C.1    Lichtenberger, C.2    Miehsler, W.3    Oberhuber, G.4    Herbst, F.5    Vogelsang, H.6    Gangl, A.7    Reinisch, W.8
  • 100
    • 14644404938 scopus 로고    scopus 로고
    • An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease
    • DOI 10.1111/j.1365-2036.2005.02287.x
    • Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 2005;21:391-400. (Pubitemid 40313941)
    • (2005) Alimentary Pharmacology and Therapeutics , vol.21 , Issue.4 , pp. 391-400
    • Korzenik, J.R.1    Dieckgraefe, B.K.2
  • 101
    • 0037048904 scopus 로고    scopus 로고
    • Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor
    • DOI 10.1016/S0140-6736(02)11437-1
    • Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyteemacrophage colony-stimulating factor. Lancet 2002;360:1478-80. (Pubitemid 35356328)
    • (2002) Lancet , vol.360 , Issue.9344 , pp. 1478-1480
    • Dieckgraefe, B.K.1    Korzenik, J.R.2
  • 103
    • 70349321253 scopus 로고    scopus 로고
    • Steroid-sparing properties of sargramostim in patients with corticosteroiddependent Crohn's disease: A randomised, double-blind, placebocontrolled, phase 2 study
    • Valentine JF, Fedorak R, Feagan BG, et al. Steroid-sparing properties of sargramostim in patients with corticosteroiddependent Crohn's disease: a randomised, double-blind, placebocontrolled, phase 2 study. Gut 2009;58:1354-62.
    • (2009) Gut , vol.58 , pp. 1354-1362
    • Valentine, J.F.1    Fedorak, R.2    Feagan, B.G.3
  • 104
    • 77953718243 scopus 로고    scopus 로고
    • Phase I trial of sargramostim in pediatric Crohn's disease
    • Kelsen JR, Rosh J, Heyman M, et al. Phase I trial of sargramostim in pediatric Crohn's disease. Inflamm Bowel Dis 2010;16:1203-8.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 1203-1208
    • Kelsen, J.R.1    Rosh, J.2    Heyman, M.3
  • 105
    • 34848858527 scopus 로고    scopus 로고
    • Efficacy and safety of sargramostim in moderate to severe Crohn's disease: Results of NOVEL 4, a Phase II multicenter study
    • Feagan BG, Anderson FH, Radford-Smith GL, et al. Efficacy and safety of sargramostim in moderate to severe Crohn's disease: results of NOVEL 4, a Phase II multicenter study. Digestive Disease Week 2007;132:A737.
    • (2007) Digestive Disease Week , vol.132
    • Feagan, B.G.1    Anderson, F.H.2    Radford-Smith, G.L.3
  • 106
    • 0027407109 scopus 로고
    • Endothelial-leukocyte adhesion molecules
    • Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804. (Pubitemid 23115023)
    • (1993) Annual Review of Immunology , vol.11 , pp. 767-804
    • Bevilacqua, M.P.1
  • 107
    • 0026770377 scopus 로고
    • Integrins: Versatility, modulation, and signaling in cell adhesion
    • Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
    • (1992) Cell , vol.69 , pp. 11-25
    • Hynes, R.O.1
  • 108
    • 53849097306 scopus 로고    scopus 로고
    • Nonimmune cells in inflammatory bowel disease: From victim to villain
    • Danese S. Nonimmune cells in inflammatory bowel disease: from victim to villain. Trends Immunol 2008;29:555-64.
    • (2008) Trends Immunol , vol.29 , pp. 555-564
    • Danese, S.1
  • 109
    • 77954179519 scopus 로고    scopus 로고
    • Anti-adhesion molecule therapy for inflammatory bowel disease
    • Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol 2010;3:239-58.
    • (2010) Therap Adv Gastroenterol , vol.3 , pp. 239-258
    • Ghosh, S.1    Panaccione, R.2
  • 110
    • 0033231492 scopus 로고    scopus 로고
    • Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis
    • Zabel BA, Agace WW, Campbell JJ, et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 1999;190:1241-56.
    • (1999) J Exp Med , vol.190 , pp. 1241-1256
    • Zabel, B.A.1    Agace, W.W.2    Campbell, J.J.3
  • 111
    • 84860582480 scopus 로고    scopus 로고
    • accessed Jul 2011
    • Food and Drug Administration. Approval of Natalizumab for Use in Crohn's disease. 2008. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2008/ 125104s0033ltr.pdf (accessed Jul 2011).
    • (2008) Approval of Natalizumab for Use in Crohn's Disease
  • 114
    • 79953801792 scopus 로고    scopus 로고
    • Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis
    • Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59.
    • (2011) Am J Gastroenterol , vol.106 , pp. 644-659
    • Ford, A.C.1    Sandborn, W.J.2    Khan, K.J.3
  • 117
    • 33644605483 scopus 로고    scopus 로고
    • Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
    • Yousry TA, Habil M, Major EO, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33.
    • (2006) N Engl J Med , vol.354 , pp. 924-933
    • Yousry, T.A.1    Habil, M.2    Major, E.O.3
  • 118
    • 79957449040 scopus 로고    scopus 로고
    • Clinical outcomes of natalizumab-associated progressive multifocal leukpencephalopathy
    • Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukpencephalopathy. Neurology 2011;76:1697-704.
    • (2011) Neurology , vol.76 , pp. 1697-1704
    • Vermersch, P.1    Kappos, L.2    Gold, R.3
  • 120
    • 57249089077 scopus 로고    scopus 로고
    • Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin
    • Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7.
    • (2008) Clin Gastroenterol Hepatol , vol.6 , pp. 1370-1377
    • Feagan, B.G.1    Greenberg, G.R.2    Wild, G.3
  • 121
    • 84927975259 scopus 로고    scopus 로고
    • The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates
    • Fedyk ER, Csizmadia V, Chyi Shyu W, et al. The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates. JCC 2011;5:2.
    • (2011) JCC , vol.5 , pp. 2
    • Fedyk, E.R.1    Csizmadia, V.2    Chyi Shyu, W.3
  • 122
    • 0032867984 scopus 로고    scopus 로고
    • ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1
    • DOI 10.1517/13543784.8.9.1417
    • Shanahan WR Jr. ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1. Expert Opin Investig Drugs 1999;8:1417-29. (Pubitemid 29417625)
    • (1999) Expert Opinion on Investigational Drugs , vol.8 , Issue.9 , pp. 1417-1429
    • Shanahan Jr., W.R.1
  • 125
    • 0036288638 scopus 로고    scopus 로고
    • Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
    • DOI 10.1136/gut.51.1.30
    • Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-6. (Pubitemid 34717740)
    • (2002) Gut , vol.51 , Issue.1 , pp. 30-36
    • Yacyshyn, B.R.1    Chey, W.Y.2    Goff, J.3    Salzberg, B.4    Baerg, R.5    Buchman, A.L.6    Tami, J.7    Yu, R.8    Gibiansky, E.9    Shanahan, W.R.10
  • 126
    • 33846804162 scopus 로고    scopus 로고
    • A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn's Disease
    • DOI 10.1016/j.cgh.2006.11.001, PII S1542356506011451
    • Yacyshyn BR, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5:215-20. (Pubitemid 46216935)
    • (2007) Clinical Gastroenterology and Hepatology , vol.5 , Issue.2 , pp. 215-220
    • Yacyshyn, B.1    Chey, W.Y.2    Wedel, M.K.3    Yu, R.Z.4    Paul, D.5    Chuang, E.6
  • 127
    • 33646237136 scopus 로고    scopus 로고
    • Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis
    • Miner PB, Geary RS, Matson J, et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 2006;23:1427-34.
    • (2006) Aliment Pharmacol Ther , vol.23 , pp. 1427-1434
    • Miner, P.B.1    Geary, R.S.2    Matson, J.3
  • 128
    • 33646271377 scopus 로고    scopus 로고
    • A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis
    • van Deventer SJ, Wedel MK, Baker BF, et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006;23:1415-25.
    • (2006) Aliment Pharmacol Ther , vol.23 , pp. 1415-1425
    • Van Deventer, S.J.1    Wedel, M.K.2    Baker, B.F.3
  • 129
    • 77957244016 scopus 로고    scopus 로고
    • Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
    • Walters MJ, Wang Y, Lai N, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010;335:61-9.
    • (2010) J Pharmacol Exp Ther , vol.335 , pp. 61-69
    • Walters, M.J.1    Wang, Y.2    Lai, N.3
  • 130
    • 84865435185 scopus 로고    scopus 로고
    • Chemokine receptor antagonist CXC282-B (Traficet-En) maintained remission of Crohn's disease in PROTECT-1 study
    • Keshav S, Johnson D, Schall T, et al. Chemokine receptor antagonist CXC282-B (Traficet-En) maintained remission of Crohn's disease in PROTECT-1 study. Digestive Disease Week 2010:A647.
    • (2010) Digestive Disease Week
    • Keshav, S.1    Johnson, D.2    Schall, T.3
  • 132
    • 79960336916 scopus 로고    scopus 로고
    • The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study
    • Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011;60:1068-75.
    • (2011) Gut , vol.60 , pp. 1068-1075
    • Vermeire, S.1    Ghosh, S.2    Panes, J.3
  • 133
    • 79955562875 scopus 로고    scopus 로고
    • Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: A randomized, double-blind, placebo-controlled trial
    • Takazoe M, Watanabe M, Kawaguchi T, et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Digestive Disease Week 2009;136:S1066.
    • (2009) Digestive Disease Week , vol.136
    • Takazoe, M.1    Watanabe, M.2    Kawaguchi, T.3
  • 134
    • 84860558067 scopus 로고    scopus 로고
    • A phase I study of rHuMab beta7 in moderate to severe ulcerative colitis
    • Rutgeerts P, Fedorak R, Hommes D, et al. A phase I study of rHuMab beta7 in moderate to severe ulcerative colitis. Digestive Disease Week 2011:A748.
    • (2011) Digestive Disease Week
    • Rutgeerts, P.1    Fedorak, R.2    Hommes, D.3
  • 135
    • 78650653452 scopus 로고    scopus 로고
    • Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: Long-term follow-up
    • Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010;116:6123-32.
    • (2010) Blood , vol.116 , pp. 6123-6132
    • Burt, R.K.1    Craig, R.M.2    Milanetti, F.3
  • 136
    • 78649895490 scopus 로고    scopus 로고
    • Autlogous bone-marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: Results of a phase I study
    • Duijvestein M, Vos AC, Roelofs H, et al. Autlogous bone-marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010;59:1662-9.
    • (2010) Gut , vol.59 , pp. 1662-1669
    • Duijvestein, M.1    Vos, A.C.2    Roelofs, H.3
  • 137
    • 79955853222 scopus 로고    scopus 로고
    • Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease
    • Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011;60:788-98.
    • (2011) Gut , vol.60 , pp. 788-798
    • Ciccocioppo, R.1    Bernardo, M.E.2    Sgarella, A.3
  • 138
    • 64049104052 scopus 로고    scopus 로고
    • Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase II clinical trial
    • Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009;52:79-86.
    • (2009) Dis Colon Rectum , vol.52 , pp. 79-86
    • Garcia-Olmo, D.1    Herreros, D.2    Pascual, I.3
  • 140
    • 77950988234 scopus 로고    scopus 로고
    • Infliximab, azathioprine, or combination therapy for Crohn's disease
    • Colombel J-F, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
    • (2010) N Engl J Med , vol.362 , pp. 1383-1395
    • Colombel, J.-F.1    Sandborn, W.J.2    Reinisch, W.3
  • 141
    • 79952783670 scopus 로고    scopus 로고
    • Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review
    • Filippi J, Allen PB, Hebuterne X, et al. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets 2011;12:1440-7.
    • (2011) Curr Drug Targets , vol.12 , pp. 1440-1447
    • Filippi, J.1    Allen, P.B.2    Hebuterne, X.3
  • 142
    • 77149169736 scopus 로고    scopus 로고
    • Early Crohn disease: A proposed definition for use in disease-modification trials
    • Peyrin-Biroulet L, Loftus EV, Colombel J-F, et al. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 2010;59:141-7.
    • (2010) Gut , vol.59 , pp. 141-147
    • Peyrin-Biroulet, L.1    Loftus, E.V.2    Colombel, J.-F.3
  • 143
    • 84855216805 scopus 로고    scopus 로고
    • Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
    • Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61(2): 241-47.
    • (2012) Gut , vol.61 , Issue.2 , pp. 241-247
    • Peyrin-Biroulet, L.1    Cieza, A.2    Sandborn, W.J.3
  • 144
    • 79955844087 scopus 로고    scopus 로고
    • Development of the Crohn's disease digestive damage score, the Lemann score
    • Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17:1415-22.
    • (2011) Inflamm Bowel Dis , vol.17 , pp. 1415-1422
    • Pariente, B.1    Cosnes, J.2    Danese, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.